Medulloblastoma
Symptoms, Doctors, Treatments, Advances & More

Medulloblastoma Overview

Save information for later
Sign Up

Learn About Medulloblastoma

View Main Condition: Brain Tumor

What is the definition of Medulloblastoma?
Medulloblastoma is a type of brain tumor that occurs in the cerebellum. The cerebellum is important for coordination, particularly balance and movement. Medulloblastoma often spreads through cerebrospinal fluid (CSF) to other areas of the brain and the spinal cord. Medulloblastoma is the most common childhood malignant brain tumor. Roughly 250-500 new cases of medulloblastoma are diagnosed each year. 
What are the causes of Medulloblastoma?
The cause of medulloblastomas is still unknown. However, medulloblastomas generally tend to be more common in children than adults. Males are also more likely to develop medulloblastomas than females.
What are the symptoms of Medulloblastoma?
Common symptoms of medulloblastoma include headaches, nausea, vomiting, fatigue, poor coordination, dizziness, or difficulty walking. If the medulloblastoma has spread to the spinal cord, symptoms may also include back pain and difficulty controlling bowel and bladder functions. 
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Medulloblastoma?
Treatment for glioma may include surgery, radiation therapy, and/or chemotherapy. Surgery to remove as much of the tumor as possible is generally the first step in treating medulloblastoma. However, if a tumor is located near a sensitive area in the brain, surgery may not be possible at all. Radiation therapy often follows surgery for the treatment of medulloblastoma. Radiation therapy involves the use of high-energy beams, including X-rays or protons, to destroy tumor cells. Chemotherapy involves the use of drugs, either taken orally or injected through a vein, to kill tumor cells. Chemotherapy is often used in combination with radiation therapy.
Who are the top Medulloblastoma Local Doctors?
Advanced in Medulloblastoma
Dr. Joel A. Kaplan
Pediatrics | Hematology | Oncology
Advanced in Medulloblastoma
Dr. Joel A. Kaplan
Pediatrics | Hematology | Oncology

Atrium Health Levine Children’s Cancer & Blood Disorders, A Facility Of Carolinas Medical Center

1001 Blythe Blvd., Suite 3000, 
Charlotte, NC 
704-381-9900
Experience:
25+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joel Kaplan is a Hematologist and a Pediatrics provider practicing medicine in Charlotte, North Carolina. He has been practicing medicine for over 25 years. Dr. Kaplan is rated as an Advanced provider by MediFind in the treatment of Medulloblastoma. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Medulloblastoma, Langerhans Cell Histiocytosis, and Bone Marrow Aspiration. Dr. Kaplan is board certified in American Board Of Pediatrics and American Board Of Pediatrics, Pediatric Hematology And Oncology. Dr. Kaplan is currently accepting new patients.

Elite in Medulloblastoma
Dr. Amar Gajjar
Hematology | Oncology
Elite in Medulloblastoma
Dr. Amar Gajjar
Hematology | Oncology

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
901-595-2615
Languages Spoken:
English
See accepted insurances

Amar Gajjar is a Hematologist and an Oncologist practicing medicine in Memphis, Tennessee. Dr. Gajjar is rated as an Elite provider by MediFind in the treatment of Medulloblastoma. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, Diffuse Midline Glioma H3 K27M-Mutant, and Posterior Fossa Decompression.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Medulloblastoma
Andrey G. Korshunov
Elite in Medulloblastoma
Andrey G. Korshunov
Heidelberg, BW, DE 

Andrey Korshunov practices practicing medicine in Heidelberg, Germany. Mr. Korshunov is rated as an Elite expert by MediFind in the treatment of Medulloblastoma. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Ependymoma.

View All Doctors
How do I prevent Medulloblastoma?
There is no known way to prevent medulloblastomas. However, if you develop any symptoms common to a medulloblastoma, it is recommended to make an appointment with your doctor to be properly diagnosed.
What are the latest Medulloblastoma Clinical Trials?
A Pilot Feasibility and Efficacy (Phase 2) Trial of Real Time Drug Screening and Genomic Testing to Determine an Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
A Pilot Feasibility and Efficacy (Phase 2) Trial of Real Time Drug Screening and Genomic Testing to Determine an Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Other
Study Phase: Not Applicable

Summary: The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in the pilot phase of performing real-time drug screening on tissue taken during surgery in patients with relapsed medulloblastoma or ependymoma and of having a specialized tumor board assign a treatment plan based on the results of this screen...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Single-arm Open-label Phase I/II Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Single-arm Open-label Phase I/II Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Enrollment Status: Recruiting
Publish Date: April 14, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)

View All Clinical Trials
What are some Advocacy Organizations?
keep-punching-brain-cancer

Keep Punching supports patients, healthcare providers, and researchers in their fight to prevent and eradicate brain cancer and minimize treatment-related side effects that may adversely impact function and comfort.